Oxford BioMedica plc -5.9% potential downside indicated by Deutsche

Oxford BioMedica plc with ticker (LON:OXB) now has a potential downside of -5.9% according to Deutsche.

OXB.L

Deutsche set a target price of 380 GBX for the company, which when compared to the Oxford BioMedica plc share price of 404 GBX at opening today (04/11/2024) indicates a potential downside of -5.9%. Trading has ranged between 164 (52 week low) and 450 (52 week high) with an average of 195,441 shares exchanging hands daily. The market capitalisation at the time of writing is £434,925,241.

Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers several technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. It has bioprocessing and manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg, France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing and process development activities undertaken for third parties. Its Viral Vector includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system.